ClinicalTrials.gg
CompletedNCT04163536CorticopUpdated Oct 23, 2026

Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICU

A Phase 3 interventional study of Methylprednisolone and Placebos in Chronic Obstructive Pulmonary Disease, sponsored by Versailles Hospital. Completed at 23 sites in France. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Versailles Hospital · Phase 3, Interventional, and Treatment

How we know

Updated Oct 23, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France — 71 open to participants now, 81 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · France.

Enrollment
90th of 286
440 · median 138
Started
2021
with 20 others
Phase 3
83 of 406
8 open now
Registered
266th of 406
by date

Among the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, this one is the 90th largest by enrollment of the 286 interventional ones that give a count, is one of 21 that started in 2021, is one of 83 in phase 3, and was the 266th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

71 of the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France are open now. Recruiting first, the newest first:

66 more — sign in →

All 71 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, or all of them as a file.
02

Study summary

The main objective of this study is to determine if the systemic (intravenous) administration of corticosteroids, as compared to placebo, increases the number of ventilator-free days (VFD) and alive at day 28 in COPD patients admitted to an ICU, a step-up unit or a respiratory care unit for an acute on chronic respiratory failure (ACRF) requiring ventilatory support, either invasive or non-invasive.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥ 40 years
  2. Strongly suspected or documented , defined by the presence of the following criterias:

    • Persistent respiratory symptoms (dyspnoea, chronic cough or sputum)
    • History of exposure to a risk factor such as tobacco smoke
    • If available, pulmonary function tests showing airflow limitation not fully reversible (post-bronchodilator ratio of / FVC ratio \< 0.7)
  3. Severe acute exacerbation, defined by the presence of the two following criteria:

    • COPD exacerbation defined by a change in the patient baseline respiratory symptoms and requiring a change in regular respiratory medication
    • Acute respiratory failure (polypnea ≥ 30 breaths.min-1 or use of accessory respiratory muscles) requiring mechanical ventilation, either invasive or NIV (implemented because of hypercapnic acidosis with PaCO2 ≥ 45 mmHg and pH ≤ 7.35).
  4. Admission to an ICU, a step-up unit or a respiratory care unit \<24h
  5. Written inform consent from the patient or his surrogates. In patients who are not able to consent on admission an emergency inclusion procedure will be allowed, with a mandatory delayed consent.
  6. Affiliation to (or benefit from) French health insurance system.

Exclusion criteria

Exclusion Criteria:

  1. Previous diagnostic of asthma ("GINA" international guidelines)
  2. Current and proven active SARS-CoV2 infection
  3. of systemic treatment: allergy to corticosteroids, uncontrolled severe arterial hypertension, uncontrolled diabetes mellitus, gastro-intestinal ulcer bleeding
  4. Underlying disease requiring chronic daily use of systemic steroids
  5. Pneumothorax at inclusion
  6. Extracorporeal life support (ECMO or ECCO2R) at inclusion
  7. Moribund patient
  8. Pregnancy
  9. Patients protected by law
  10. Exclusion period due to other interventional clinical trial enrolment which can influence primary outcome
  11. Previous inclusion in the present study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
440 participants (actual)

Study arms

  • Active comparator
    cortisteroids arm

    Drug: Methylprednisolone

  • Placebo comparator
    placebo arm

    Drug: Placebos

Interventions

  • In the experimental group, methylprednisolone will be administered intravenously for 5 days at a dose of 1 mg/kg/day. Methylprednisolone will be provided for reconstitution and dilution in 50 ml of NaCl 0.9% solution and administered over 15 minutes, once a day.

  • DrugPlacebos

    in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.

06

What researchers measure

Primary outcomes

  1. the number of ventilator-free days (VFD) and alive at day 28.

    To determine if the systemic administration of corticosteroids, as compared to placebo, increases the number of ventilator-free days (VFD) and alive at day 28 in COPD patients admitted to an ICU, a step-up unit or a respiratory care unit for an ACRF requiring ventilatory support, either invasive or non-invasive.

    Time frame: day 28

Secondary outcomes

  1. NIV failure rate

    NIV failure rate, defined by intubation within day 7

    Time frame: day 7

  2. Duration of NIV and of invasive mechanical ventilation

    Duration of Non Invasive Ventilation and of invasive mechanical ventilation

    Time frame: at day 90

  3. Circulatory and renal support-free days and alive at day 28

    Circulatory and renal support-free days and alive at day 28

    Time frame: at day 28

  4. Severe hyperglycemia requiring intravenous insulin during the five first days

    Severe hyperglycemia requiring intravenous insulin during the five first days

    Time frame: during the five first days

  5. Gastro-intestinal bleeding

    acute loss of 2 g/dL of hemoglobin requiring red blood cell transfusion or gastroscopic evaluation

    Time frame: between inclusion and day 28

  6. Uncontrolled arterial hypertension

    unusual hypertension requiring to introduce/add antihypertensive medication (compared to usual medications)

    Time frame: between inclusion and day 28

  7. ICU acquired weakness (MRC-score < 48/60) assessed on day 28 or at the time of ICU discharge

    Intensive Care Unit acquired weakness (MRC-score \< 48/60) assessed on day 28 or at the time of ICU discharge

    Time frame: at day 28

  8. ICU-acquired infections (especially Ventilator-Associated Pneumonia)

    Intensive Care Unit -acquired infections (especially Ventilator-Associated Pneumonia)

    Time frame: at the time of ICU discharge or day 90

  9. Length of ICU and hospital stay

    Length of ICU and hospital stay

    Time frame: at day 90

  10. ICU and hospital mortality

    ICU and hospital mortality

    Time frame: between inclusion and day 28 or day 90

  11. Day 28 and Day 90 mortality

    Day 28 and Day 90 mortality

    Time frame: at Day 28 and Day 90

  12. Standardized mortality ratio (SMR)

    Standardized mortality ratio (SMR)

    Time frame: between inclusion and day 90

  13. Number of new exacerbation(s)/hospitalization(s) between hospital discharge and Day 90

    Number of new exacerbation(s)/hospitalization(s) between hospital discharge and Day 90

    Time frame: at day 90

  14. Dyspnea (patient reported outcome) at Day 90 evaluated by clinical assessment test and dyspnea mMRC score

    Dyspnea (patient reported outcome) at Day 90 evaluated by clinical assessment test and dyspnea mMRC score

    Time frame: at day 90

  15. respiratory comfort (patient reported outcome) at Day 90 evaluated by clinical assessment test and dyspnea mMRC score

    respiratory comfort (patient reported outcome) at Day 90 evaluated by clinical assessment test and dyspnea mMRC score

    Time frame: at day 90

07

Study locations

23 sites
  • CHU de Bicêtre
    Le Kremlin-Bicêtre, France 94270, France
  • André Mignot Hospital, Intensive care unit
    Le Chesnay, Les Yvelines 78150, France
  • CHU Angers
    Angers, France
  • CH Argenteuil
    Argenteuil, France
  • CH métropole savoie
    Chambéry, France
  • CHU Louis Mourier
    Colombes, France
  • CHU Dijon
    Dijon, France
  • CHU Grenoble
    Grenoble, France
  • CHD Vendée
    La Roche-sur-Yon, France
  • CH Le Mans
    Le Mans, France
  • CHRU lille
    Lille, France
  • CHU Lyon
    Lyon, France
  • CH d'Annecy Genevois
    Metz-Tessy, 74370, France
  • CHU Nice
    Nice, France
  • CHR orléans
    Orléans, France
  • CHU Cochin
    Paris, France
  • Hôpital européen Georges pompidou
    Paris, France
  • Pitié-Salpêtrière
    Paris, France
  • CHU Poitiers
    Poitiers, France
  • CHU de Rennes
    Rennes, France
  • Hopital Foch
    Suresnes, France
  • CHRU Tours
    Tours, France
  • CH Vannes
    Vannes, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Nov 2024, 36 months.

Of 33 non-industry phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 56. This study's 36 months is close to that.

Counting every sponsor, half of 142 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Oct 2025 → Nov 2024 and completion Mar 2026 → Apr 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2019
First posted
Nov 14, 2019
StartActual
Oct 25, 2021
Primary completionActual
Nov 24, 2024was Oct 2025
CompletionActual
Apr 17, 2025was Mar 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 23, 2026
Sites
4 sites added, 4 sites removed
Show 4 added (4 France)
  • CHU de Bicêtre · Le Kremlin-Bicêtre, France
  • CH Argenteuil · Argenteuil, France
  • CHU Nice · Nice, France
  • CH Vannes · Vannes, France
Show 4 removed
  • CHU Henri mondor · Créteil, France
  • CHU de Bicêtre · Le Kremlin-Bicêtre, France
  • CHU Nantes · Nantes, France
  • CHU de Rouen · Rouen, France
Oct 23, 2026
Primary completion
Oct 25, 2025→Nov 24, 2024 (actual)
Oct 23, 2026
Study completion
Mar 1, 2026→Apr 17, 2025 (actual)
Oct 23, 2026
Eligibility
5 inclusion criteria edited; 3 exclusion criteria edited, 2 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedACRFSevere acute exacerbation, defined by the presence of the two following criteria:
  • EditedCOPD exacerbation defined by a change in the patient baseline respiratory symptoms at least 24 hours and requiring a change in regular respiratory medication
  • EditedAcute respiratory failure <24h (polypnea ≥ 30 breaths.min-1 or use of accessory respiratory muscles) requiring ventilatory supportmechanical ventilation, either invasive (implemented because of respiratory distress) or NIV (implemented because of hypercapnic acidosis with PaCO2 ≥ 45 mmHg and pH ≤ 7.35).
  • EditedAdmission to an ICU, a step-up unit or a respiratory care unit <24h
  • EditedInformWritten inform consent from the patient or his surrogates. In patients who are not able to consent on admission an emergency inclusion procedure will be allowed, with a mandatory delayed consent.
Exclusion criteria
  • EditedPrevious diagnostic of asthma, according to ("GINA" international guidelines (40)
  • RemovedRecent use of systemic corticosteroids, defined by systemic corticosteroids use in the past 7 days
  • AddedCurrent and proven active SARS-CoV2 infection
  • AddedUnderlying disease requiring chronic daily use of systemic steroids
  • EditedPneumothorax at randomizationinclusion
  • ChangedBefore Moribund patient life expectancy < 3 monthsNow Moribund patient
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Completed
    4 sites added, 4 sites removed
    Show 4 added (4 France)
    • CHU de Bicêtre · Le Kremlin-Bicêtre, France
    • CH Argenteuil · Argenteuil, France
    • CHU Nice · Nice, France
    • CH Vannes · Vannes, France
    Show 4 removed
    • CHU Henri mondor · Créteil, France
    • CHU de Bicêtre · Le Kremlin-Bicêtre, France
    • CHU Nantes · Nantes, France
    • CHU de Rouen · Rouen, France
    Primary completion Oct 25, 2025→Nov 24, 2024 (now actual)
    Study completion Mar 1, 2026→Apr 17, 2025 (now actual)
    Eligibility 5 inclusion criteria edited; 3 exclusion criteria edited, 2 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedACRFSevere acute exacerbation, defined by the presence of the two following criteria:
    • EditedCOPD exacerbation defined by a change in the patient baseline respiratory symptoms at least 24 hours and requiring a change in regular respiratory medication
    • EditedAcute respiratory failure <24h (polypnea ≥ 30 breaths.min-1 or use of accessory respiratory muscles) requiring ventilatory supportmechanical ventilation, either invasive (implemented because of respiratory distress) or NIV (implemented because of hypercapnic acidosis with PaCO2 ≥ 45 mmHg and pH ≤ 7.35).
    • EditedAdmission to an ICU, a step-up unit or a respiratory care unit <24h
    • EditedInformWritten inform consent from the patient or his surrogates. In patients who are not able to consent on admission an emergency inclusion procedure will be allowed, with a mandatory delayed consent.
    Exclusion criteria
    • EditedPrevious diagnostic of asthma, according to ("GINA" international guidelines (40)
    • RemovedRecent use of systemic corticosteroids, defined by systemic corticosteroids use in the past 7 days
    • AddedCurrent and proven active SARS-CoV2 infection
    • AddedUnderlying disease requiring chronic daily use of systemic steroids
    • EditedPneumothorax at randomizationinclusion
    • ChangedBefore Moribund patient life expectancy < 3 monthsNow Moribund patient
    + 4 other changes: verification date, description, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04163536
Lead sponsor
Versailles Hospital
Responsible party
Alexis FERRE (coordinating investigator, Versailles Hospital) — Principal investigator
First posted
Nov 14, 2019
Start date
Oct 25, 2021
Primary completion
Nov 24, 2024
Completion
Apr 17, 2025
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylprednisolone

Start the discussion